Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 6/20 | 0.64 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.60 |
| ▸ | FNTA | P49354 | 12/20 | 0.50 |
| ▸ | FNTB | P49356 | 12/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10654112 | 0.86 | GRIA4 (0.61) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL10653103 | 0.78 | GRIA4 (0.50) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3126194 | 0.78 | GRIA4 (0.80) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL10653341 | 0.77 | GRIA4 (0.94) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3128982 | 0.77 | FNTA (0.78) | GRIA4GRIA2FNTAFNTBKDM4E | |
| SCHEMBL16792125 | 0.77 | GRIA4 (0.78) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL2980278 | 0.76 | FNTA (0.48) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL3125313 | 0.75 | GRIA4 (1.00) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL9865512 | 0.74 | GRIA4 (0.48) | GRIA4GRIA2FNTAFNTBKMT2A | |
| SCHEMBL10656067 | 0.74 | GRIA4 (0.80) | GRIA4GRIA2FNTAFNTBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389206-B1 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7084159-B2 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1389206-A2 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20040023963-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | CAO JINGRONG (US) | 2004-02-05 | — | — | US | disclosed |
| US-6642227-B2 | Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents | VERTEX PHARMACEUTICALS INCORPORATED | 2003-11-04 | — | — | US | disclosed |
| US-20030096816-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002083667-A2 | INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023963-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | LCK, MAPK1, MAP3K1 | GRIA4 2812/4885GRIA2 2604/4885FNTA 2906/4885 |
| US-20030096816-A1 | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases | LCK, MAPK1, MAP3K1 | GRIA4 2812/4885GRIA2 2604/4885FNTA 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.